Recovery From Acute Immune Failure in Septic Shock by Immune Cell Extracorporeal Therapy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

142 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-01-01

Study Completion Date

2030-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Subjects previously enrolled / randomized in the ReActIF-ICE (Recovery from acute immune failure in septic shock by immune cell extracorporeal terapy - immune competence enhancement) study received either standard sepsis treatment (control group) or standard sepsis treatment and additionally the ARTICE treatment (treatment group) during their index hospitalization. All subjects are followed up for 90 days after enrollment.

In this long term follow up study, the enrolled subjects shall be followed up beyond 90 days for up to 5 years.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

NCT05442710

Sepsis, Severe

RECRUITING PHASE2

The Effects of Interferon-gamma on Sepsis-induced Immunoparalysis

NCT01649921

Sepsis Septic Shock

COMPLETED PHASE3

Reconstruction of Monocytic Immunocompetence by Granulocyte-macrophage-colony Stimulating Factor (GM-CSF) in Patients With Severe Sepsis and Septic Shock

NCT00252915

Sepsis

COMPLETED PHASE2

Extracorporeal Immune Support System (EISS) for the Treatment of Septic Patients

NCT00818597

Severe Sepsis and Septic Shock

COMPLETED PHASE1/PHASE2

Acute Phase Proteins as Early Markers in Sepsis

NCT00641355

Sepsis

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Sepsis is a worldwide health threat because of high mortality and the development of long-lasting disabilities, including physical and cognitive impairment and mental disorders, known collectively as post-intensive care syndrome (PICS), which contribute to reduced health-related quality of life (HRQoL) for several years even after successful recovery from the initial acute sepsis state. Sepsis survivors often need a longer period of rehabilitation, consuming more medical and social resources and struggle with financial burdens.

In the ReActIF-ICE study, that started enrolling patients in July 2022, up to 142 subjects with severe sepsis are to be enrolled and randomized into a therapy group (receiving the ARTICE treatment (extracorporeal immune cell plasma perfusion) on top of standard care) and control group (standard care only). These subjects were followed up according the ReActIF-ICE study protocol for 90 days.

Since there is still a large need for long-term outcome data of sepsis patients, collecting data of the ReActIF-ICE patients over a longer period of time would provide important additional information regarding:

1. General long term clinical and socio-economic outcome of sepsis survivors
2. Long-term outcome details of the ReActIF-ICE patient population
3. The potential long-term medical outcome effects of the additional ARTICE treatment compared to standard treatment alone.
4. The potential long-term health-related quality-of-life effects of ReActIF-ICE patient population
5. The potential long-term health-related quality-of-life effects of the additional ARTICE treatment compared to standard treatment alone.

In this long term follow up study, the enrolled subjects shall be followed up beyond 90 days for up to 5 years.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Severe Sepsis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Control group

Subjects in this group where randomized in the control group in the ReActiF-ICE study previously

No interventions assigned to this group

Therapy Group

Subjects in this group where randomized in the therapy group in the ReActiF-ICE study previously

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Subject or legal surrogate is willing and able to provide written informed consent and comply with all protocol requirements or the implementation of other established procedures according to the local regulations of the contributing center to include subjects who are unable to provide informed consent.
2. Subject was enrolled in the ReActIF-ICE study and successfully passed the Day 2 re-evaluation of that trial.